Verve Ventures

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Neo Medical SA is a medical technology company based in Villette, Switzerland, with additional offices in Germany, France, and the United States. Founded in 2013, the company specializes in developing, manufacturing, and commercializing non-constraint thoraco-lumbar spinal fusion systems for spinal surgery. Its flagship product, the Neo Pedicle Screw System, offers a range of functionalities such as reduction, compression, distraction, and screw augmentation, addressing various pathologies including degenerative conditions, tumors, and trauma. Neo Medical aims to enhance the efficiency of healthcare delivery by providing versatile and high-quality surgical solutions, thereby contributing to the ongoing pursuit of healthcare cost optimization.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

MedTrace Pharma A/S, founded in 2015 and based in Kongens Lyngby, Denmark, specializes in the development of innovative solutions for positron emission tomography (PET) imaging. The company has created an automated system, known as MT-100, which efficiently produces and injects 15O-water, a radioactive tracer essential for enhanced imaging. This system is designed to integrate seamlessly with in-house cyclotrons and PET scanners, significantly increasing the sensitivity of patient analysis while improving throughput by up to four times compared to conventional methods. Additionally, MedTrace Pharma develops the aQuant analytical platform, which aids in interpreting PET scan results, further optimizing the diagnostic process. With additional offices in Boston, Massachusetts, and Uppsala, Sweden, MedTrace is focused on advancing the capabilities of clinical imaging through automation and innovative technology.

Therapixel SA is a company based in Valbonne, France, with additional locations across multiple countries, including Australia and China. Founded in 2013, Therapixel specializes in designing and developing medical image analytics software for surgeons, leveraging artificial intelligence to enhance surgical procedures. Their product portfolio includes Radvise, an automatic image reading solution; Fluid, a touchless medical image navigation system for surgery; Anywhere, a post-processing workstation; and CD-Feed, a solution for importing CDs from outpatient imaging exams. The company also focuses on AI-based software for breast cancer detection and characterization, providing healthcare professionals with pertinent information to support decision-making during surgeries while adhering to sterility constraints.

Sleepiz AG, founded in 2018 and headquartered in Zurich, Switzerland, specializes in manufacturing a non-contact sleep disorder-screening device. The product monitors breathing, heart rate, and body movements with medical-grade accuracy using wireless millimeter wave technology, sensor fusion, and artificial intelligence. This device is designed to be placed on the bedside table for easy use, enabling healthcare professionals to monitor patients' sleep patterns from home. Sleepiz aims to facilitate long-term monitoring of chronic diseases, allowing for faster intervention and improved treatment outcomes.

Medimaps Group develops medical software that enhances osteoporosis diagnosis by assessing bone microarchitecture. Its AI-driven imaging tools help clinicians select appropriate treatments and monitor outcomes, with future applications in dental and orthopedic fields.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

Sleepiz AG, founded in 2018 and headquartered in Zurich, Switzerland, specializes in manufacturing a non-contact sleep disorder-screening device. The product monitors breathing, heart rate, and body movements with medical-grade accuracy using wireless millimeter wave technology, sensor fusion, and artificial intelligence. This device is designed to be placed on the bedside table for easy use, enabling healthcare professionals to monitor patients' sleep patterns from home. Sleepiz aims to facilitate long-term monitoring of chronic diseases, allowing for faster intervention and improved treatment outcomes.

EarlySight, a Lausanne-based medical device company, develops technology to detect and treat eye diseases at an early stage. Its flagship work includes a fundus camera that images the retina with high detail by combining eye illumination with real time ocular aberration correction. The company also leverages cellular level imaging and transscleral illumination to monitor day to day treatment effects in a non invasive manner, enabling eye specialists to visualize the morphology of retinal cells. Founded in 2016, EarlySight aims to bring its imaging technology to clinics to improve early diagnosis and treatment of ocular conditions.

Founded in 2017, Perfood is a German digital therapeutics startup that offers personalized nutrition-based therapies via an application. It focuses on weight management and migraine prevention by analyzing sensor data, lab results, and holistic analyses to derive tailored therapeutic solutions.

Neo Medical SA is a medical technology company based in Villette, Switzerland, with additional offices in Germany, France, and the United States. Founded in 2013, the company specializes in developing, manufacturing, and commercializing non-constraint thoraco-lumbar spinal fusion systems for spinal surgery. Its flagship product, the Neo Pedicle Screw System, offers a range of functionalities such as reduction, compression, distraction, and screw augmentation, addressing various pathologies including degenerative conditions, tumors, and trauma. Neo Medical aims to enhance the efficiency of healthcare delivery by providing versatile and high-quality surgical solutions, thereby contributing to the ongoing pursuit of healthcare cost optimization.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

Aktiia is a company focused on providing continuous and accurate blood pressure monitoring to address hypertension, a prevalent chronic condition affecting over 1.4 billion people globally. Founded on two decades of research, Aktiia has developed a unique tool that combines optical sensors with clinically validated software algorithms to measure blood pressure at the wrist. This innovative approach enables individuals to gain insights into their blood pressure patterns and understand the underlying causes of hypertension. By delivering personalized, continuous, and medical-grade blood pressure and heart rate data, Aktiia aims to enhance patient care and empower patients, researchers, and clinicians. The company's mission is to improve the accessibility, accuracy, and actionability of blood pressure management, ultimately contributing to better health outcomes and reducing the significant mortality associated with high blood pressure.

Founded by experts in DNA sequencing and diagnostic analyses in oncology, OncoDNA offers precision medicine solutions for cancer treatment. It provides clinical guidance for late-stage patients, supports research, and aids drug development.

PathoQuest SAS, a spin-off from Institut Pasteur, is a biotechnology company specializing in advanced pathogen detection through metagenomics. The company employs next-generation sequencing (NGS) based testing to provide actionable reports for clinicians, biologists, and quality assurance managers in the biopharmaceutical industry. PathoQuest's proprietary sample preparation methods and extensive database of pathogen genomic information address current limitations in infectious agent detection. Their Viral Safety testing service, aimed at biopharmaceutical companies, has already generated revenue from several major firms, showcasing the company’s innovative approach to molecular diagnostics.

RetinAI Medical AG, founded in 2016 and headquartered in Bern, Switzerland, focuses on developing innovative software tools for the collection, organization, and analysis of eye health data. The company offers products such as OmniViewer, which enables researchers to annotate and structure both 2D and 3D datasets for machine learning and statistical analyses, and Discovery, designed for clinical and pharmaceutical research. RetinAI aims to optimize and simplify workflows in clinics and research environments, enhancing healthcare delivery by leveraging advanced machine learning for automatic image and data analysis. Its proprietary technology significantly improves image quality and facilitates the automatic analysis of medical data for hospitals, private practitioners, pharmaceutical companies, and device manufacturers, achieving performance levels comparable to human analysis.

Piavita AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing advanced technology for the veterinary industry. The company has created a compact, matchbox-sized wearable device that accurately measures vital medical data from pets, including horses, without the need for clipping fur or extensive preparation. This innovative system is complemented by a web-based application that enables real-time monitoring and historical tracking of vital signs, improving the diagnostic capabilities available to veterinarians. By providing reliable insights into pet health and facilitating better communication between pet owners and veterinary professionals, Piavita aims to lead the digital transformation of veterinary care, addressing the gaps in current veterinary practices and enhancing the overall wellbeing of animals.

Luciole Medical AG is a Swiss medical technology company that specializes in the design and manufacture of brain oxygenation monitoring systems. Founded in 2017 and based in Zurich, the company has developed a platform that accurately measures the levels of oxygenated and deoxygenated hemoglobin, as well as cerebral blood flow and other critical parameters. Its product lineup includes RheoPatch, a non-invasive sensor applied to the skin to assess oxygen metabolism and blood flow; RheoSens, an implantable probe that measures various cerebral metrics; RheoLity, which offers software for data display, analysis, and patient management; and RheoControl, which connects to medical monitors for data visualization. Luciole Medical's systems enable healthcare professionals to monitor cerebral oxygenation effectively, providing crucial insights into the patient's brain health.

Pregnolia AG, established in 2015 and headquartered in Zurich, Switzerland, specializes in the development of a diagnostic device that predicts the risk of premature birth during pregnancy. The company's core product is a medical probe that measures the strength of the uterine cervix, empowering healthcare professionals to intervene preventively and enhance neonatal health outcomes. Pregnolia's mission is to ensure every woman experiences a happy, healthy, and informed pregnancy, working closely with pregnant women and gynecologists to achieve this goal. The company is committed to completing clinical trials, navigating regulatory pathways, and commercializing its device to successfully support gynecologists in improving preterm birth risk assessment and management.

DBS System SA is a medtech company based in the Swiss Health Valley that specializes in the production of HemaXis™ blood collection devices. The company utilizes advanced microfluidic technology to create innovative devices designed for the less invasive, safer, and more efficient collection and preparation of blood samples. HemaXis devices facilitate plasma and serum extraction with precision and in a standardized format, significantly enhancing the capabilities of dried blood spot samples in bioanalysis. By streamlining blood collection processes, DBS System aims to support health monitoring and testing while contributing to the advancement of personalized medicine and big data initiatives.

Piavita AG, founded in 2016 and headquartered in Zurich, Switzerland, specializes in developing advanced technology for the veterinary industry. The company has created a compact, matchbox-sized wearable device that accurately measures vital medical data from pets, including horses, without the need for clipping fur or extensive preparation. This innovative system is complemented by a web-based application that enables real-time monitoring and historical tracking of vital signs, improving the diagnostic capabilities available to veterinarians. By providing reliable insights into pet health and facilitating better communication between pet owners and veterinary professionals, Piavita aims to lead the digital transformation of veterinary care, addressing the gaps in current veterinary practices and enhancing the overall wellbeing of animals.

Clinpal is a technology-driven company that specializes in enhancing the efficiency and effectiveness of clinical trials through its cloud-based platform. The platform is designed to support virtual, hybrid, and direct-to-patient studies by streamlining patient recruitment, engagement, retention, and data acquisition throughout the clinical trial process. Clinpal offers a comprehensive workflow and communication engine that connects all stakeholders, including patients, clinical research associates, and sponsors, thereby improving collaboration and data quality in real time. Its intelligent data hub consolidates biometric data reported by patients or clinicians, ensuring that high-quality information is readily available. Clinpal’s scalable architecture and flexible licensing options make it suitable for a diverse range of clinical trials, ultimately helping healthcare clients achieve better trial outcomes and productivity.

MEDUDEM Corp. is a company in the digital health sector that focuses on the improvement of collaboration and interaction of all participants involved around chronic diseases (CCM). On the basis of its readily available web- and mobile-based solutions Care Integrator® and Healthbrain®, MEDUDEM Corp. improves collaboration and exchanges between medical professionals and patients, as well as third-party organizations. This provides clear advantages and synergetic benefits for all parties in and around the healthcare market and ensures the interaction and communication in a simple, fast and comprehensive way and manner.